Bumpus Namandje sold $13K of RXRX
Bumpus Namandje sold 3,963 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.18 on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan.
Market read
This provides a fresh datapoint on insider activity but does not introduce new operational, clinical, or financial guidance.
What to watch
Traders may overreact to small insider sales; the more actionable signal would be repeated large discretionary sales or changes in insider buying patterns.
Background
The article is a SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals.
Ticker impact
Recursion Pharmaceuticals disclosed an insider open-market sale by director Bumpus Namandje of 3,963 shares at $3.1800 on 2026-06-18.
Limited immediate price impact; any effect is likely short-lived unless follow-on insider selling accelerates.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBumpus Namandje
Director who sold 3,963 shares in an open-market transaction under a 10b5-1 plan.
